Here are 1-3 brief analogies for Sutro Biopharma (STRO):

• It's like an early-stage Moderna, but focused on creating novel protein therapeutics for cancer and autoimmune disorders using its proprietary cell-free synthesis platform, rather than mRNA.

• It's like an early-stage Seagen (a pioneer in antibody-drug conjugates), but building its next-generation ADC and protein drug pipeline with its unique cell-free synthesis platform.

• It's like an innovative biotech company, similar to an early-stage Genentech or Amgen, but leveraging its unique cell-free protein synthesis platform to develop advanced protein-based medicines.

• STRO-001: An antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.
• STRO-002: An antibody-drug conjugate (ADC) directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

Sutro Biopharma (STRO) sells primarily to other companies. Its major customers, based on collaboration and license agreements, include:

• Merck (MRK)
• Celgene Corporation (now part of Bristol Myers Squibb, BMY)

Jane Chung, R.Ph. Chief Executive Officer

Jane Chung was appointed Chief Executive Officer of Sutro Biopharma in March 2025. She brings over 20 years of leadership experience in the pharmaceutical and biotechnology sectors. Prior to her CEO role, she served as Sutro's President and Chief Operating Officer from December 2023, and as Chief Commercial Officer starting in August 2021. Before joining Sutro, Ms. Chung held several leadership positions at AstraZeneca, including President and General Manager of AstraZeneca Canada, and Vice President of Sales and Marketing of U.S. Immuno-Oncology. Her earlier career included commercial roles at Onyx Pharmaceuticals Inc. and Genentech, Inc. Ms. Chung also serves on the Board of Directors of Viracta Therapeutics, Inc.

Greg Chow, M.B.A. Chief Financial Officer

Greg Chow was appointed Chief Financial Officer of Sutro Biopharma effective June 2, 2025. He has over 25 years of experience encompassing corporate finance, capital markets, investment banking, financial accounting, and drug development operations. Mr. Chow's previous roles include Chief Financial Officer and Chief Business Officer at NodThera, Chief Financial Officer at Freenome Holdings, Inc., Chief Financial Officer at Frontier Medicines Corp., and Executive Vice President and Chief Financial Officer at Aptose Biosciences, Inc. He was instrumental in financing efforts at these companies, supporting a Series F funding round for Freenome Holdings, guiding Frontier Medicines through Series B and C financings, and leading Aptose Biosciences' dual listing on Nasdaq and the Toronto Stock Exchange while helping raise over $225 million in capital. Earlier in his career, he spent fourteen years in investment banking, holding leadership positions at Wedbush Securities, RBC Capital Markets, and Wells Fargo Securities.

David Pauling, J.D., M.A. Chief Administrative Officer and General Counsel

David Pauling has served as Chief Administrative Officer and General Counsel of Sutro Biopharma since April 2025. He joined Sutro in 2011 and has held positions of increasing responsibility within the company, including Intellectual Property Counsel, Associate General Counsel, Senior Intellectual Property Counsel, and Executive Director of Legal Affairs. In his current role, he is responsible for all aspects of Sutro's legal operations, including governance, compliance, disclosure, intellectual property, and agreements. Before joining Sutro, Mr. Pauling practiced law at Jones Day and Pennie & Edmonds, LLP. He holds a J.D. from Santa Clara University School of Law, and an M.A. in Molecular Biology and a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz.

Hans-Peter Gerber, Ph.D. Chief Scientific Officer

Hans-Peter Gerber has served as Chief Scientific Officer of Sutro Biopharma since September 2023. He brings over three decades of research and development experience in oncology drug development, with deep expertise in antibody-drug conjugates (ADCs), redirected T-cell engagers, and cell-based immunotherapies. Dr. Gerber co-founded Codeable Therapeutics in 2022 and previously served as Chief Scientific Officer and Senior Vice President at 3T Biosciences. He built the R&D organization at Maverick Therapeutics, which was acquired by Takeda in 2021, and also served as an independent director at NBE Therapeutics, acquired by Boehringer Ingelheim in 2021. Earlier in his career, he held scientific leadership roles at Genentech, Seattle Genetics, and Pfizer, contributing to numerous IND filings and three Biologics License Applications (BLAs), including Avastin®, Mylotarg®, and Besponsa®. Dr. Gerber has contributed to the development of six of the 15 FDA-approved ADCs. He received his M.S. in Biochemistry and Ph.D. in Molecular Biology from the University of Zurich, Switzerland.

Devendra Luhar Senior Vice President, Technical Operations

Devendra Luhar currently serves as Senior Vice President, Technical Operations at Sutro Biopharma. He joined Sutro in 2016 as Senior Director of Manufacturing and was promoted to Executive Director in 2018, and later to Vice President of Manufacturing & Plant Operations in August 2020. Mr. Luhar has over 30 years of experience in biotech operations, covering manufacturing, manufacturing science and technology, engineering, and logistics. At Sutro, he has been instrumental in establishing the company's manufacturing organization and GMP compliant operations, and he is responsible for Sutro's cGMP manufacturing facility. Prior to joining Sutro, he held senior leadership positions at companies such as Boehringer-Ingelheim, Novartis, Genzyme, Arbor Vita Corporation, and Baxter BioScience. Mr. Luhar holds a B.A. in Biology from San Jose State University.

The key risks to Sutro Biopharma's business are primarily associated with the inherent challenges of drug development, intense market competition, and ongoing funding requirements.

1. Clinical Trial Failure and Regulatory Hurdles: As a clinical-stage biopharmaceutical company, Sutro Biopharma's success is highly dependent on its product candidates proving safe and effective in clinical trials and subsequently gaining regulatory approval. All of Sutro's internal product candidates are currently in early-stage development, with STRO-001 in Phase 1 clinical trials and the company shifting focus to earlier-stage candidates like STRO-004, which is in preclinical development. There is a significant risk that positive preclinical data will not translate into clinical success in humans, and many companies in the biotechnology industry have experienced setbacks in late-stage trials despite promising early results. The process of obtaining regulatory approval is complex, time-consuming, and uncertain, and the failure of any product candidate in trials or to secure approval would materially harm the business. The effective discontinuation of luveltamab tazevibulin (formerly STRO-002) further highlights the significant challenges and high failure rates in drug development.
2. Intense Competition and Market Position: Sutro Biopharma operates within the highly competitive oncology sector, specifically in the rapidly evolving field of Antibody-Drug Conjugates (ADCs). The market includes numerous established pharmaceutical companies and new entrants developing similar therapies. This crowded landscape makes it challenging for Sutro to differentiate its product candidates, especially given their early stage of development. For example, the folate receptor-alpha (FRα) targeting ADC market, which included Sutro's deprioritized luveltamab (STRO-002), is increasingly competitive with other approved products and those under development. The company's ability to successfully advance its pipeline and secure partnerships is crucial for its long-term prospects in this dynamic environment.
3. Funding Requirements and Potential Dilution: As a company with no products currently on the market, Sutro Biopharma generates minimal revenue, primarily relying on collaborations, and incurs significant losses due to substantial research and development costs. Advancing its product candidates through various clinical development stages requires considerable financial resources. While the company has secured funding, there is an ongoing need for additional capital, which may be obtained through equity offerings, potentially leading to shareholder dilution. The discontinuation of a late-stage asset, such as luveltamab-T, could also impact investor confidence and make it more challenging to secure future funding or partnerships.

Sutro Biopharma (NASDAQ: STRO) develops protein therapeutics for cancer and autoimmune disorders. The addressable markets for its main product candidates are substantial and global.

STRO-001 (Antibody-Drug Conjugate targeting CD74)

• Multiple Myeloma: The global multiple myeloma market was estimated at $27.75 billion in 2024, with projections to reach approximately $49.89 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 6.04% from 2025 to 2034. Another source indicates the global market size was valued at $29.24 billion in 2025, and is projected to grow to $49.79 billion by 2034, exhibiting a CAGR of 6.10% during the forecast period. The 7 Major Markets (7MM) for multiple myeloma reached a value of $16.4 billion in 2023 and are projected to reach $38.1 billion by 2034, with an 8% CAGR.
• Non-Hodgkin Lymphoma (NHL): The global non-Hodgkin lymphoma therapeutics market is valued at $10.99 billion in 2025 and is predicted to increase to approximately $20.94 billion by 2034, expanding at a CAGR of 7.43% from 2025 to 2034. The global non-Hodgkin lymphoma treatment market size was valued at $11.59 billion in 2025 and is projected to reach $19.44 billion by 2034, exhibiting a CAGR of 6.25%.

STRO-002 (Antibody-Drug Conjugate targeting Folate Receptor-Alpha)

• Ovarian Cancer: The global ovarian cancer market was estimated at $3.83 billion in 2024 and is forecast to grow from $4.08 billion in 2025 to $6.81 billion by 2033, at a CAGR of 6.70%. Another report estimates the global market size at $3.5 billion in 2023, with a projected CAGR of 7.2% from 2024 to 2032, reaching approximately $6.5 billion by 2032. Specifically for ovarian cancer, the market is projected to reach $5.1 billion by 2032.
• Endometrial Cancers: The 7 Major Markets (7MM) for endometrial cancer reached a value of $21.4 billion in 2024 and are expected to reach $31.2 billion by 2035, exhibiting a growth rate (CAGR) of 3.52% during 2025-2035. The global endometrial cancer market is valued at $19.52 billion in 2024 and is projected to reach a value of $29.44 billion by 2035 at a CAGR of 3.80% between 2025 and 2035. Another source indicates the global endometrial cancer market size is calculated at $31.09 billion in 2025 and is expected to reach around $51.15 billion by 2034, expanding at a CAGR of 5.69% from 2025 to 2034.

Sutro Biopharma (STRO) is expected to drive future revenue growth over the next 2-3 years primarily through a combination of strategic collaborations and the advancement of its proprietary clinical pipeline. Given its status as a clinical-stage biopharmaceutical company, significant product sales within this timeframe are unlikely; instead, revenue will largely be generated from partnership activities and milestone achievements.

The key drivers of future revenue growth for Sutro Biopharma are:

1. Achievement of Milestones from Existing Strategic Partnerships: Sutro Biopharma has established collaborations, notably with Astellas, that are anticipated to yield milestone payments as partnered candidates progress through development. The Astellas partnership, for instance, has a first candidate expected to enter the clinic in 2026. Additionally, the company's existing agreements with Merck and Bristol-Myers Squibb (formerly Celgene) also present opportunities for milestone payments based on research and development achievements.
2. Entry into New Collaboration and Licensing Agreements: The company is actively pursuing new partnership opportunities to enhance its competitive position. New collaborations typically involve upfront payments and potential future development and regulatory milestones, which would contribute to revenue growth within the specified timeframe.
3. Progress of Wholly-Owned Pipeline Candidates Through Clinical Development: While direct product sales from Sutro's wholly-owned pipeline are not expected in the near term, successful advancement of its lead programs through clinical trials can trigger significant milestone payments from existing or future partners. Specifically, STRO-004, a lead oncology candidate, is in Phase 1 with key data expected in mid-2026. Another candidate, STRO-006, an ITGB6-targeting exatecan ADC for lung cancer, is projected to have an Investigational New Drug (IND) submission in 2026. Positive clinical validation of these programs could attract new collaborations or expand existing ones, leading to revenue generation.

Share Issuance

• In February 2026, Sutro Biopharma priced an underwritten public offering of 7,868,383 shares of common stock at $13.98 per share, expecting to generate approximately $110.0 million in gross proceeds.
• In December 2025, the company implemented a 1-for-10 reverse stock split.
• In April 2024, Sutro Biopharma raised $75 million through an underwritten offering of common stock.

Inbound Investments

• Sutro Biopharma received $75 million in upfront payments and an equity investment from Ipsen in April 2024, for licensing exclusive global rights to STRO-003.
• Revenue for the year ended December 31, 2024, was $62.0 million, primarily derived from collaborations with Astellas and the Tasly agreement.
• For the year ended December 31, 2023, the company reported revenues of $153.7 million.

Outbound Investments

• In 2024, the company realized a gain of $32.1 million from the sale of Vaxcyte common stock.

Capital Expenditures

• Sutro Biopharma plans to decommission its internal GMP manufacturing facility by year-end 2025, transitioning to an external manufacturing strategy.
• Cash payments estimated to be between $40 million and $45 million are expected to result from a strategic portfolio review and related restructuring in 2025, which includes the manufacturing facility transition.
• Proceeds from the February 2026 underwritten offering are intended for general corporate purposes, including funding capital expenditures.